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Abstract
Advances in diabetes technologies have enabled the development of automated closed-loop insulin delivery systems. Several
hybrid closed-loop systems have been commercialised, reflecting rapid transition of this evolving technology from research into
clinical practice, where it is gradually transforming the management of type 1 diabetes in children and adults. In this review we
consider the supporting evidence in terms of glucose control and quality of life for presently available closed-loop systems and
those in development, including dual-hormone closed-loop systems. We also comment on alternative ‘do-it-yourself’ closed-
loop systems. We remark on issues associated with clinical adoption of these approaches, including training provision, and
consider limitations of presently available closed-loop systems and areas for future enhancements to further improve outcomes
and reduce the burden of diabetes management.
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Abbreviations
AHCL Advanced hybrid closed-loop
App Application (mobile phone)
CGM Continuous glucose monitor
DIY Do-it-yourself
MPC Model predictive control
PID Proportional integral derivative
Introduction and development of closed-loop
systems
Hybrid closed-loop insulin delivery systems are gradually
transforming clinical management of type 1 diabetes. They
comprise a subcutaneously worn continuous glucose monitor
(CGM or glucose sensor) device, communicating with an
algorithm that responds in real time to changes in sensor
glucose levels, and adjusts the subcutaneous insulin infusion
delivered by an insulin pump (Fig. 1).
Although the concept of glucose-responsive insulin deliv-
ery has been around for 50 years, earlier developments of
closed-loop systems were hampered by the lack of accurate
and reliable CGM systems, unavailability of wearable compu-
tational devices and secure wireless communication protocols,
and challenged by limitations in insulin pump devices. With
advances in CGM technology, the simplest form of automated
insulin delivery was achieved with low-glucose suspend
systems, where insulin delivery is suspended when the sensor
glucose crosses a specified threshold, and predictive glucose
management systems, where insulin delivery is suspended
when an algorithm predicts that sensor glucose is likely to
cross the low-glucose threshold [1, 2]. These systems reduce
hypoglycaemia, although sometimes at the expense of
increased hyperglycaemia [3]. These were conceptually land-
mark steps in the journey towards fully automated insulin
delivery and a true ‘artificial pancreas’ (Fig. 2).
A closed-loop system is a more sophisticated system, with
a control algorithm adjusting insulin delivery (up and down)
in response to real-time sensor glucose levels and other inputs,
such as meal intake (Fig. 3). The algorithm can accommodate
variability of insulin requirements between and within indi-
vidual users, and account for limitations of CGM accuracy
and imprecisions of subcutaneous insulin delivery.
Adaptation of the control algorithm to changes in physiolog-
ical conditions with real-time adjustment of closed-loop
control parameters is beneficial for optimal performance.
Several different types of control algorithm have been devel-
oped, including model predictive control (MPC) algorithms,
proportional integral derivative (PID) controllers and fuzzy
logic control approaches [4]. MPC algorithms calculate
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insulin delivery by minimising the difference between model-
predicted glucose concentrations and target glucose over a
pre-specified prediction time horizon. PID controllers adjust
insulin delivery by assessing glucose excursions from three
perspectives: (1) deviation from target glucose (proportional
component); (2) area under the curve between measured and
target glucose (integral component); and (3) rate of change of
measured glucose (derivative component). The fuzzy logic
approach modulates insulin delivery based on approximate
rules to express empirical knowledge of diabetes practitioners.
The first commercial closed-loop system, the MiniMed
670G (Medtronic, Northridge, CA, USA) was approved by
the US Food and Drug Administration in September 2016 for
use in people with type 1 diabetes aged 14 years and older [5].
This hybrid closed-loop system requires users tomanually enter
prandial insulin with automation of insulin delivery between
meals and overnight. Several other hybrid closed-loop systems
have since been commercialised and are increasingly being
utilised in routine clinical care for people with type 1 diabetes.
Efficacy and safety of hybrid closed-loop
systems
Clinical studies evaluating the safety and efficacy of hybrid
closed-loop systems have evolved from small, highly supervised
studies, undertaken overnight or over 24 h in research facilities, to
larger randomised controlled trials of unrestricted home living
use, conducted over 6 months or longer. A meta-analysis,









Fig. 1 Schematic of the configuration of closed-loop insulin delivery. A
CGM transmits information about interstitial glucose concentrations to an
algorithm hosted on a smartphone or insulin pump that translates infor-
mation from the glucose sensor and computes the amount of insulin to
deliver. An insulin pump delivers a rapid-acting insulin analogue
subcutaneously. Insulin delivery is modulated in real time by the control
algorithm. Communication between system components is wireless.
CSII, continuous subcutaneous insulin infusion. Figure adapted from
[36]. This figure is available as part of a downloadable slideset
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downloadable slideset
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efficacy and safety of hybrid closed-loop systems in people with
type 1 diabetes [6]. Earlier closed-loop systems were associated
with a 9.6 percentage point improvement in time in target glucose
range (3.9–10.0 mmol/l) compared with comparator therapies
(>2 additional h/day) and reduced time in hypoglycaemia
(<3.9 mmol/l) by 1.5 percentage points (approximately 20 min/
day) compared with control treatment. Hybrid closed-loop
systems have a favourable effect on HbA1c, with a reduction of
0.3–0.4% compared with control therapy in studies with a dura-
tion of more than 8 weeks per intervention. While this effect
appears modest, this is despite the reduction in hypoglycaemia
observed in several of these studies, as well as the low HbA1c at
recruitment, reflecting good baseline glycaemic control of study
participants. Similar benefits have been reported in a meta-
analysis of 25 studies in the paediatric population [7].
Individual randomised controlled trials demonstrate
glycaemic benefits of hybrid closed-loop systems vs compar-
ator therapies, but comparisons of efficacy between hybrid
closed-loop systems across different studies is hampered by
variation in baseline characteristics of participants, study dura-
tion and design. Studies including participants with variable
experience in diabetes technology use (on multiple daily insu-
lin injections and without previous sensor use) and from more
diverse socioeconomic backgrounds are important to support
generalisability of benefits.
Psychosocial impact of closed-loop systems
The impact of closed-loop technology on quality-of-life
measures has been explored in several studies [8].
Psychosocial benefits reported by users include reduced anxi-
ety, improved sleep and confidence from improved overnight
glucose control, less restrictive eating habits and ‘time off’
from the demands of diabetes management. Reported chal-
lenges include technical issues, alarm intrusiveness and equip-
ment burden, in addition to initial difficulties trusting the
system. Most participants in closed-loop studies report that
they would continue using closed-loop therapy or would
recommend it to others as the clinical benefits outweigh
system shortcomings. Psychosocial studies have largely
included participants involved in closed-loop trials who may
not be representative of the wider population living with type
1 diabetes.
Commercially available closed-loop systems
Details of the commercially available hybrid closed-loop
systems can be found in Table 1 and an overview of key
clinical studies are shown in Table 2.
Medtronic 670G and 780G Safety and efficacy of the first
commercially approved hybrid closed-loop system
(Medtronic 670G insulin pump with Guardian 3 sensor) was
evaluated in a non-randomised before-and-after study in 30
adolescents and 94 adults with type 1 diabetes, over 3 months
(Table 2) [9]. The proportion of time spent in target glucose
range (3.9–10 mmol/l) increased from 60% at baseline to 67%
with the closed-loop system in adolescents, and from 69% to
74% in adults. Time spent in hypoglycaemia (<3.9 mmol/l)
was reduced with the closed-loop system and there were no
Fig. 3 Hybrid closed-loop
glucose control. (a) 24 h of sensor
glucose data. Green shaded area is
the target glucose range (3.9–
10 mmol/l). Green triangles
indicate carbohydrate (carbs)
intake. (b) Algorithm-driven
insulin delivery and manual
insulin boluses. Data in both
graphs derived from a Cambridge
closed-loop study participant (the
individual provided permission to
share this anonymised data for the
purpose of advancement of
science). The graphs were
generated using the data
management platform Diasend
(https://diasend.com//en). Image
credit: Glooko Inc. All rights
reserved. 2021. The x-axes show
time in hours. This figure is
available as part of a
downloadable slideset
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episodes of severe hypoglycaemia or diabetic ketoacidosis in
the study. A similar before-and-after study evaluating use of
this device in 105 younger children aged 7–13 years reported
increased time in target range and reduced time in
hypoglycaemia with the closed-loop system (Table 2) [10].
A second-generation advanced hybrid closed-loop (AHCL
[780G, Medtronic]) system has been developed to further
improve glycaemic control and usability, with adjustable
target glucose and automated correction boluses. The Fuzzy
Logic Automated Insulin Regulation (FLAIR) study directly
compared the Medtronic 670G with the AHCL system in
adolescents and young adults with type 1 diabetes. Time in
target glucose range was higher with the AHCL system than
with the Medtronic 670G, while time in hypoglycaemia was
similar (Table 2). The AHCL system was associated with
fewer system alerts, reduced Auto Mode exits and increased
time spent in Auto Mode (86% vs 75%) [11].
Tandem control-IQ In the longest randomised controlled
closed-loop study to date, involving 168 people with type 1
diabetes (age ≥ 14 years), the Control-IQ system (t:slim X2
pump with Dexcom G6 sensor [Tandem, San Diego, CA,
USA]) was compared with sensor-augmented pump therapy
over 6 months (Table 2; Fig. 4) [12]. Time in target glucose
range increased by 10 percentage points from baseline with
the closed-loop system (61% to 71%) while there was no
change in the control group (59% to 59%). Time spent in
hypoglycaemia was reduced with the closed-loop system
compared with the control group and there was an
improvement in HbA1c. Notably, all participants completed
the study, suggesting high acceptability of the technology.
In another study, the Control-IQ system was compared
with sensor-augmented pump therapy in 101 younger children
with type 1 diabetes, aged 6–13 years, over 16 weeks
(Table 2). The closed-loop group had significantly greater
improvements in time in target range, while the time spent
in hypoglycaemia was similar between the closed-loop and
control groups [13].
CamAPS FX CamAPS FX is the first interoperable hybrid
closed-loop mobile phone application (app), utilising a control
algorithm developed at the University of Cambridge
(CamDiab; Cambridge, UK). At present, the app, hosted on
an unlocked android smartphone, communicates with the
Dana RS and Dana-i pumps and the Dexcom G6 sensor, but
will communicate with additional pump and CGM systems in
the future. The algorithm has been extensively evaluated in
randomised controlled studies including children, adolescents,
adults and pregnant women with type 1 diabetes [14, 15]. In a
randomised controlled trial including 86 children and adults
with sub-optimal glycaemic control (baseline HbA1c >
58mmol/mol [7.5%]), closed-loop use increased time in target
range over 12 weeks compared with sensor-augmented pump
therapy (Table 2) [16]. Time spent in hypoglycaemia was
lower in the closed-loop group than the control group and
HbA1c also improved with closed-loop use.
Closed-loop insulin delivery using the Cambridge algo-
rithm has been demonstrated to be feasible even in the very
Table 1 Commercially available hybrid closed-loop systems
Component Medtronic 670G Medtronic 780G CamAPS FX Control-IQ
Algorithm PID with insulin feedback PID with insulin feedback Treat to target adaptive
MPC
(Cambridge algorithm)
Treat to range predictive
algorithm
Insulin pump 670G 780G Dana RS, Dana-i Tandem t:slim X2



















Optional activity target Optional activity target Night mode: 6.2–6.7 mmol/l
Optional activity target Optional activity target
Algorithm
learning
















TDD, total daily dose
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youngest of children, aged 1–7 years. In a study comparing
the Cambridge closed-loop system using diluted insulin with
the same closed-loop system using standard-strength insulin
in children aged 2–7 years old, time in target glucose range
was >70% and time in hypoglycaemia was <5% during both
interventions. There were no safety or efficacy benefits of
diluted insulin use compared with use of standard-strength
insulin (Table 2) [17].
In a randomised controlled study involving 16 pregnant
women with type 1 diabetes, closed-loop use overnight was
associated with increased time in the tighter glucose range
recommended during pregnancy (3.5–7.8 mmol/l) compared
with sensor-augmented pump therapy (75% vs 60%), without
increasing the risk of hypoglycaemia [14]. During the contin-
uation phase, the closed-loop system was used 24 h/day,
including during labour and delivery, and time in target
glucose range was 69%.
Anticipated commercial hybrid closed-loop
systems
The Diabeloop hybrid closed-loop system, comprising a
handset containing the algorithm, Kaleido pump and
Dexcom G6 sensor (DBLG1; Diabeloop, Grenoble, France),
has been compared with sensor-augmented pump therapy in
68 adults with type 1 diabetes, in the home setting, with
remote monitoring over 12 weeks [18]. Time with glucose
in target range was 9 percentage points greater with closed-
loop therapy than with control therapy (69% vs 59%) and time
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• TIR ↑ from 60%
(baseline) to 67%
• TBR ↓ from 4.3%
(baseline) to 2.8%
Adults:
• TIR ↑ from 69%
(baseline) to 74%
• TBR ↓ from 6.4%
(baseline) to 3.4%
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7.9% (63 mmol/mol) • TIR ↑ from 56%
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• TIR ↑: 67% vs 63%
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• TBR ↓: 1.6% vs 2.3%
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comparing Control-IQ
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3 weeks n =24 children
(2–7 years old)
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• TIR: 70–72%
• TBR: 4.5–4.7%
SAP, sensor-augmented pump; TBR, time below range (<3.9 mmol/l); TIR, time in range (3.9–10 mmol/l)
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in hypoglycaemia was significantly lower with closed-loop
use than during the control period. The DBLG1 hybrid
closed-loop system has received the CE mark for use in adults
with type 1 diabetes and is due to be commercialised.
The Insulet Omnipod Horizon hybrid closed-loop system,
comprising the Omnipod pump and Dexcom G6 sensor
(Insulet, Billerica, MA, USA), and Beta Bionics insulin-only
iLet hybrid closed-loop system, comprising the iLet Bionic
Pancreas System and Dexcom G6 sensor (Beta Bionics,
Boston, MA, USA), are both currently being evaluated in
pivotal trials with launches anticipated in the next 1–2 years.
Do-it-yourself closed-loop systems
The do-it-yourself (DIY) artificial pancreas system (DIYAPS)
communities arose out of their frustration with the slow progress
of medical device development cycles (the #wearenotwaiting
movement). The communities develop and apply open-access
closed-loop systems (e.g. the Open Artificial Pancreas System
[OpenAPS], Loop and AndroidAPS), which do not undergo
regulatory overview and approval. Without needing to await
regulatory approval for new developments, these systems benefit
from more rapid innovation cycles and can be more flexible in
terms of customisation. In principle, access is open to anyone but
users must be able to build and maintain their own system, albeit
with support from the community itself. The role of healthcare
providers in supporting the use of unregulated systems continues
to be debated.
Several thousands of individuals use DIY systems globally.
Observational before-and-after studies show improvements in
time in target glucose range, HbA1c and quality of life, but no
longitudinal randomised controlled trials have evaluated the
efficacy and safety of these systems [19]. A randomised clin-
ical trial of a version of AndroidAPS is underway
(ACTRN12620000034932p).
Dual-hormone closed-loop systems
The physiological glucagon response to hypoglycaemia is
often impaired in type 1 diabetes; therefore, addition of gluca-
gon to a closed-loop system confers additional protection from
hypoglycaemia and may allow more aggressive insulin deliv-
ery to achieve improved glucose control. Potential benefits are
countered by increased system complexity, requirement for
two separate infusion systems and the lack of approved
room-temperature-stable glucagon for chronic subcutaneous
delivery. There are currently no commercially available
dual-hormone closed-loop systems, although several are in
development.
The longest dual-hormone closed-loop home study, with
remote monitoring, included 43 adults with type 1 diabetes
with optional meal announcements over a period of 11 days.
Time in target glucose range was increased (78% vs 62%) and
hypoglycaemia (<3.3 mmol/l) was reduced (0.6% vs 1.9%)
with dual-hormone closed-loop use compared with insulin
pump therapy alone [20]. A shorter study, over 5 days, involv-
ing 32 adolescents with type 1 diabetes, demonstrated a 21
percentage point increase in time in target glucose range
during the closed-loop period compared with the control peri-
od, but time in hypoglycaemia was similar between groups
[21]. An outpatient study of over 60 h compared dual-
hormone with single-hormone closed-loop systems in 23
adults with type 1 diabetes and showed no difference in time
in target glucose range (79% vs 75%) or time in
hypoglycaemia (<4.0 mmol/l; 3.6% vs 3.9%), but longer stud-
ies are required to fully investigate potential differences [22].
Pramlintide is an analogue of amylin, which is co-secreted
with insulin from beta cells and reduces postprandial glucose
excursions by slowing gastric emptying [23]. A novel dual-
hormone closed-loop system delivering a fixed ratio of
pramlintide:insulin was evaluated during a 24 h inpatient
study in adults with type 1 diabetes. The dual-hormone system
improved time in target range compared with an insulin-alone
Fig. 4 Median percentage time with sensor glucose in target range during
closed-loop insulin delivery (red line) and sensor-augmented pump ther-
apy (blue line) in adults and adolescents ≥14 years of age, using the
Tandem Control-IQ closed-loop system [12]. The red and blue shaded
areas indicate the interquartile range for each treatment. Figure adapted
from [12]. Copyright: ©2019 Massachusetts Medical Society. Reprinted
with permission from Massachusetts Medical Society. This figure is
available as part of a downloadable slideset
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system (84% vs 74%), an effect attributable to improved
daytime glucose control [24]. Gastrointestinal symptoms were
reported more frequently during use of closed-loop systems
with pramlintide as compared with insulin only. Pramlintide
co-delivery may support the development of fully closed-loop
systems, obviating the need for manually initiated prandial
insulin delivery.
Training considerations
High quality user and healthcare professional training is
essential for ensuring that the clinical benefits of hybrid
closed-loop systems are realised in the real-world setting.
This is an important consideration for health economic analy-
ses, to support adoption, implementation and reimbursement.
Establishing realistic expectations of hybrid closed-loop ther-
apy and reiterating the importance of core diabetes skills and
tasks is important to promote long-term use and optimal clin-
ical outcomes. Training programmes have been developed,
using online and face-to-face approaches, to support users to
maximise glycaemic and quality-of-life benefits of closed-
loop therapy [25].
Limitations of closed-loop systems
Early real-world use of the first commercially approved
hybrid closed-loop system (Medtronic 670G) exposed issues
around usability. The system required significant user input to
remain in Auto Mode and, in one prospective observational
study, one-third of users discontinued use of Auto Mode
during the first year after initiation [26]. Factors influencing
discontinuation include CGM issues (calibrations), number of
alarms and efforts to limit Auto Mode exits [27]. Usability
issues can prevent realisation of the benefits of closed-loop
systems as increased time in Auto Mode is associated with
improved glycaemic outcomes [28].
Some first-generation hybrid closed-loop systems use a
relatively high glucose target (6.7 mmol/l) and lack flexibility
to adjust the target to suit the needs of the user. This makes the
system unsuitable for those aiming for tighter glycaemic
control, including pregnant women.
Postprandial glucose excursions remain a challenge for
closed-loop systems due to inherent delays in subcutaneous
insulin absorption. User interaction with accurate carbohy-
drate counting and pre-meal bolusing is required for optimal
glycaemic control. Attempts to reduce user burden with
simplified meal boluses or fully closed-loop systems have
resulted in compromised glycaemic control [29, 30].
Managing physical activity can be challenging primarily
due to increased hypoglycaemia risk and altered insulin sensi-
tivity. Even with closed-loop glucose-responsive insulin
delivery, users usually need to plan for exercise, announcing
exercise to the algorithm in advance, and may still require
carbohydrate intake to prevent hypoglycaemia [31, 32].
Carbohydrate loading before exercise can be problematic with
glucose-responsive insulin delivery, often resulting in
hypoglycaemia during exercise.
Important ethical considerations include ensuring equitable
access, training and support for closed-loop technology, and
protecting user confidentiality and safety from security
breaches [33].
Future developments in automated insulin
delivery
Future closed-loop systems will benefit from improved indi-
vidual components; smaller, more accurate CGMdevices with
longer wear-time and smaller insulin pumps with the user
interface transferred to a smartphone/watch will improve
usability and minimise device burden. Interoperable devices
and data management platforms offer flexibility for users to
create their own personalised closed-loop ecosystem.
The introduction of new faster-acting insulin analogues
(Fiasp and Ultra-Rapid Lispro) provides an opportunity to
potentially improve performance of closed-loop systems with
faster onset and offset of insulin action following subcutane-
ous delivery. Short studies comparing faster-acting insulin
with standard insulin using the Medtronic 670G system have
not shown significant benefits, but longer studies are required
to fully evaluate closed-loop systems with faster-acting insulin
[34, 35]. Faster-acting insulins are not yet approved for use in
the t:slim X2 pump and, hence, the Control-IQ closed-loop
system.
Integration of additional signals to algorithms, such as heart
rate or accelerometery, to more quickly detect physical activ-
ity than with CGM alone, may reduce exercise-related
hypoglycaemia. If efficacious, this would be particularly
beneficial in young children in whom activity is usually spon-
taneous and unpredictable and hypoglycaemia is a major
concern.
Conclusions
The last 5 years has seen the successful transition of closed-
loop systems from research into routine clinical practice for
management of type 1 diabetes. There is still scope for further
improvements to optimise postprandial glucose control, exer-
cise management and usability before this technology can be
said to truly ameliorate the burden of diabetes. Widespread
adoption and reimbursement of closed-loop systems will be
critical to ensuring equitable access to this technology.
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